DB15843Investigational
The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate... As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence Phase 1 clinical trials of this vaccine (NCT04449276).
- Mechanism
- Curator reviewed
Pharmacologically active on Spike glycoprotein
- Also known as
- CVnCoV · CVnCoV Vaccine
- Code names
- CV07050101
Resolves to
Compound
Targets
What you can answer from here — as of July 08, 2026
Which drugs share a target with Zorecimeran, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account